# Acrivon Therapeutics, Inc.: filings

ACRV · Nasdaq · CIK 1781174 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/acrv.md) · [Financials](/companies/acrv/financials.md) · [Filings](/companies/acrv/filings.md) · [Insiders](/companies/acrv/insiders.md)

## Reports and events: 71 filings

Newest first, by EDGAR acceptance time (Eastern). Filter with ?form= one of: `periodic`, `8-K`, `10-K`, `10-Q`, `4`, `proxy`, `13dg`, `all`, or any form this company filed (4 184, 8-K 43, 3 21, 10-Q 12, SC 13G/A 10, S-8 8, SCHEDULE 13G/A 7, CORRESP 5, DEFA14A 5, SC 13G 5, 10-K 4, ARS 4, DEF 14A 4, UPLOAD 4, EFFECT 3, 144 2, D 2, S-1/A 2, S-3 2, SC 13D/A 2, SCHEDULE 13D/A 2, SEC STAFF LETTER 2, 3/A 1, 424B4 1, 8-A12B 1, CERT 1, DEFR14A 1, DRS 1, DRS/A 1, DRSLTR 1, FWP 1, S-1 1, S-1MEF 1, SC 13D 1, SCHEDULE 13G 1).

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-08-12 | 16:10 ET | [8-K](/filings/0001193125-26-346859.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-346859 |
| 2026-08-12 | 16:05 ET | [10-Q](/filings/0001193125-26-346819.md) | Quarterly report, period 2026-06-30 | 0001193125-26-346819 |
| 2026-06-17 | 17:28 ET | [8-K](/filings/0001193125-26-274410.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-274410 |
| 2026-05-13 | 16:12 ET | [10-Q](/filings/0001193125-26-221634.md) | Quarterly report, period 2026-03-31 | 0001193125-26-221634 |
| 2026-05-13 | 16:10 ET | [8-K](/filings/0001193125-26-221626.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-221626 |
| 2026-04-30 | 08:30 ET | [DEF 14A](/filings/0001193125-26-194206.md) | Proxy statement, period 2026-06-17 | 0001193125-26-194206 |
| 2026-04-23 | 16:29 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000116.md) | Ownership report, active investor, amended | 0001346824-26-000116 |
| 2026-03-23 | 16:28 ET | [SCHEDULE 13D/A](/filings/0001346824-26-000081.md) | Ownership report, active investor, amended | 0001346824-26-000081 |
| 2026-03-19 | 07:21 ET | [8-K](/filings/0001193125-26-115139.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-115139 |
| 2026-03-19 | 07:10 ET | [10-K](/filings/0001193125-26-115123.md) | Annual report, period 2025-12-31 | 0001193125-26-115123 |
| 2026-03-02 | 16:30 ET | [8-K](/filings/0001193125-26-085516.md) | 1.02 Termination of a material agreement | 0001193125-26-085516 |
| 2026-02-27 | 09:00 ET | [8-K](/filings/0001193125-26-079500.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-079500 |
| 2026-01-08 | 09:00 ET | [8-K](/filings/0001193125-26-007077.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-007077 |
| 2026-01-08 | 07:30 ET | [8-K](/filings/0001193125-26-007007.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-007007 |
| 2025-11-13 | 16:17 ET | [10-Q](/filings/0001193125-25-280215.md) | Quarterly report, period 2025-09-30 | 0001193125-25-280215 |
| 2025-11-13 | 16:10 ET | [8-K](/filings/0001193125-25-280172.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-280172 |
| 2025-09-05 | 16:25 ET | [8-K](/filings/0001193125-25-197250.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-197250 |
| 2025-08-13 | 16:16 ET | [10-Q](/filings/0000950170-25-108054.md) | Quarterly report, period 2025-06-30 | 0000950170-25-108054 |
| 2025-08-13 | 16:15 ET | [8-K](/filings/0001193125-25-179834.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-179834 |
| 2025-06-13 | 16:28 ET | [8-K](/filings/0000950170-25-086246.md) | 5.07 Shareholder vote results | 0000950170-25-086246 |
| 2025-05-14 | 16:16 ET | [10-Q](/filings/0000950170-25-071427.md) | Quarterly report, period 2025-03-31 | 0000950170-25-071427 |
| 2025-05-14 | 16:10 ET | [8-K](/filings/0000950170-25-071385.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-25-071385 |
| 2025-04-25 | 08:30 ET | [DEF 14A](/filings/0000950170-25-058352.md) | Proxy statement, period 2025-06-13 | 0000950170-25-058352 |
| 2025-04-07 | 16:05 ET | [8-K](/filings/0000950170-25-051576.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-051576 |
| 2025-03-27 | 16:48 ET | [8-K](/filings/0000950170-25-046163.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-25-046163 |
| 2025-03-27 | 16:06 ET | [10-K](/filings/0000950170-25-046056.md) | Annual report, period 2024-12-31 | 0000950170-25-046056 |
| 2025-03-25 | 17:15 ET | [8-K](/filings/0000950170-25-044549.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-25-044549 |
| 2025-03-14 | 16:44 ET | [8-K](/filings/0000950170-25-039520.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0000950170-25-039520 |
| 2024-11-13 | 07:06 ET | [10-Q](/filings/0000950170-24-125929.md) | Quarterly report, period 2024-09-30 | 0000950170-24-125929 |
| 2024-11-13 | 07:00 ET | [8-K](/filings/0000950170-24-125920.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-125920 |
| 2024-10-11 | 08:00 ET | [8-K](/filings/0000950170-24-114213.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-114213 |
| 2024-09-16 | 06:43 ET | [8-K](/filings/0001193125-24-219180.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-24-219180 |
| 2024-08-13 | 08:00 ET | [8-K](/filings/0000950170-24-095766.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-095766 |
| 2024-08-13 | 07:36 ET | [10-Q](/filings/0000950170-24-095760.md) | Quarterly report, period 2024-06-30 | 0000950170-24-095760 |
| 2024-06-21 | 17:36 ET | [8-K](/filings/0000950170-24-075760.md) | 5.07 Shareholder vote results | 0000950170-24-075760 |
| 2024-05-14 | 08:00 ET | [8-K](/filings/0000950170-24-059097.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-059097 |
| 2024-05-14 | 07:31 ET | [10-Q](/filings/0000950170-24-059084.md) | Quarterly report, period 2024-03-31 | 0000950170-24-059084 |
| 2024-04-26 | 08:30 ET | [DEF 14A](/filings/0000950170-24-048671.md) | Proxy statement, period 2024-06-20 | 0000950170-24-048671 |
| 2024-04-24 | 16:01 ET | [8-K](/filings/0000950170-24-047560.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0000950170-24-047560 |
| 2024-04-11 | 16:16 ET | [SC 13D/A](/filings/0001104659-24-046306.md) | Ownership report, active investor, amended | 0001104659-24-046306 |
| 2024-04-09 | 07:05 ET | [8-K](/filings/0000950170-24-042789.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0000950170-24-042789 |
| 2024-03-28 | 08:00 ET | [8-K](/filings/0000950170-24-037627.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0000950170-24-037627 |
| 2024-03-28 | 07:36 ET | [10-K](/filings/0000950170-24-037618.md) | Annual report, period 2023-12-31 | 0000950170-24-037618 |
| 2024-03-04 | 08:15 ET | [8-K](/filings/0001193125-24-056937.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-056937 |
| 2024-02-08 | 08:27 ET | [8-K](/filings/0001193125-24-027629.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001193125-24-027629 |
| 2024-01-08 | 07:28 ET | [8-K](/filings/0001193125-24-003885.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-24-003885 |
| 2023-12-08 | 16:21 ET | [8-K](/filings/0001193125-23-291705.md) | 1.01 Entry into a material agreement | 0001193125-23-291705 |
| 2023-11-09 | 09:12 ET | [8-K](/filings/0001193125-23-274124.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-274124 |
| 2023-11-09 | 08:02 ET | [10-Q](/filings/0000950170-23-061553.md) | Quarterly report, period 2023-09-30 | 0000950170-23-061553 |
| 2023-09-05 | 17:23 ET | [8-K](/filings/0001193125-23-228639.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-23-228639 |

Page 1 of 2. [Older](/companies/acrv/filings.md?page=2)
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 26, 2026, 16:05 ET. No prices; not investment advice.